Moonshot AI Executives Seek Settlement Ahead of Hong Kong IPO 
European Stocks Rise as Oil Prices Fall Ahead of US CPI 
Most Americans Oppose Election Betting on Prediction Markets, Poll Finds 
Asian Stocks Plunge as AI Chip Selloff Hits South Korea and Japan 
Oil Prices Fall as Trump Ceasefire Claim Shifts Market Focus to U.S. CPI 
Samsung, SK Hynix Shares Fall as China's CXMT Advances DRAM Technology 
Airbus Tests Valkyrie Combat Drone in Europe for Eurofighter Integration 
Orsted to Take Full Ownership of UK Offshore Wind Farm for £15 Million 
Nasdaq Falls as Oil Prices Surge Ahead of Bank Earnings 
Oil Prices Rise as Houthi Attacks Threaten Middle East Supply 
S&P 500 Rally Masks Losses for Over 40% of Stocks in 2026 
Nvidia’s China AI Chip Market Share Falls to 34% as Huawei Gains Ground 
European Auto Stocks Rise as EU-China Trade Deal Targets Hybrid Imports 
Binance to Shut Down Crypto Mining Pool Services on November 10 
Trump Secures Russian Diesel Deal as US Fuel Prices Surge 
Deutsche Bank CEO Urges Faster German Economic Reforms 
Canton Network Expands in South Korea With Major Partnerships 
Add as a preferred source on Google
Samsung Biologics is expanding its CMO or contract manufacturing organization business, and as part of its plans, it is constructing its very first overseas production plant in the United States.
On Monday, June 13, Samsung Biologics’ chief executive officer, John Rim, shared that they are considering several locations for the facility. He said that the strongest candidates for their CMO site are Texas, North Carolina, California, and Washington.
According to The Korea Herald, Samsung Biologics is looking into these places more because many of the major bio companies’ facilities are also operating in the mentioned US states. At this time, the company has not yet made any decision and carefully reviewing the areas to choose the best option.
“We are certainly expanding and the Plant 4 will begin partial operation in October, adding a 60,000-liter production capacity,” the Samsung Biologics’ CEO told the media during the press meeting for the 2022 BIO International Convention in San Diego, California. “By the second quarter of next year, it will have a 180,000-liter production capacity.”
While planning to build its first manufacturing plant abroad, Samsung Biologics has already set up its fourth factory in Songdo, Incheon, in South Korea. Once this facility starts operating at its full capacity, it is expected to boost production.
All in all, the four plants should produce 620,000 liters of products for around 30% of the global demand. It was said that Samsung Biologics’ Plant 4 currently has the biggest CMO production capacity in the world, with 256,000 liters of products in a single facility.
Rim revealed that they are also aiming to build the fifth and sixth factories in South Korea, and this is why they are buying more land in Incheon. The purchases were originally expected to be completed by the end of May, but the authorities could not sign the contract because the government officials who are in charge, which are the mayor and commissioner of the Incheon Free Economic Zone, have changed due to the local elections that was held earlier this month.
Finally, the Samsung Biologics chief said that they still plan to go ahead with the construction of Plant 5 and 6. However, they will not be monitoring the supply and demand trends to see if there is still a need to build more factories.
